Transition Therapeutics Inc

TTH-T

0.00
0.00 (0.00%)
This company is not ACTIVE.

Analysis and Opinions about TTH-T

Signal
Opinion
Expert
COMMENT
COMMENT
September 7, 2007
As it looked at this in the last couple of months, but likes their Alzheimer's drug. Pure biotech, where they're burning money every quarter is not easy for him.
Show full opinionHide full opinion
As it looked at this in the last couple of months, but likes their Alzheimer's drug. Pure biotech, where they're burning money every quarter is not easy for him.
BUY
BUY
May 24, 2007
In general, he does not like Biotech's but he likes this company a lot. Looking at introducing therapy into the Alzheimer's stage, which would be disease altering, which would reverse the effects. Have good US partners. Likes for the long term.
Show full opinionHide full opinion
In general, he does not like Biotech's but he likes this company a lot. Looking at introducing therapy into the Alzheimer's stage, which would be disease altering, which would reverse the effects. Have good US partners. Likes for the long term.
BUY WEAKNESS
BUY WEAKNESS
March 26, 2007
In diabetes and Alzheimer therapies. Alzheimer is a disease-altering drug, not just the symptoms. Could be 5 to 10 years. If you can, trade around the volatility. Excellent long-term upside.
Show full opinionHide full opinion
In diabetes and Alzheimer therapies. Alzheimer is a disease-altering drug, not just the symptoms. Could be 5 to 10 years. If you can, trade around the volatility. Excellent long-term upside.
BUY
BUY
January 24, 2007
In diabetes, but their big upside now is in their Alzheimer’s work. Their therapy is the only one that could be disease changing, not just the symptoms. It will take 5-7 years to prove it out.
Show full opinionHide full opinion
In diabetes, but their big upside now is in their Alzheimer’s work. Their therapy is the only one that could be disease changing, not just the symptoms. It will take 5-7 years to prove it out.
STRONG BUY
STRONG BUY
December 14, 2006
Generally stays away from pure biotech. Interesting diabetes play, but likes it for the Alzheimer’s play. Has a drug that could be disease altering as opposed to symptom altering. It’ll be years before it comes through as a drug, but if it does, sales will be massive.
Show full opinionHide full opinion
Generally stays away from pure biotech. Interesting diabetes play, but likes it for the Alzheimer’s play. Has a drug that could be disease altering as opposed to symptom altering. It’ll be years before it comes through as a drug, but if it does, sales will be massive.
HOLD
HOLD
March 27, 2006
Wouldn't be the best company in the biotechnology space. Not a bad company.
Show full opinionHide full opinion
Wouldn't be the best company in the biotechnology space. Not a bad company.
BUY
BUY
January 13, 2005
Has been consolidating around the $1 for some time. Seeing some selling pressures re: warrants that were converted. A relatively high risk name, but if they are successful across one or two of the different platforms they have, stock could be significantly higher. Good management team.
Show full opinionHide full opinion
Has been consolidating around the $1 for some time. Seeing some selling pressures re: warrants that were converted. A relatively high risk name, but if they are successful across one or two of the different platforms they have, stock could be significantly higher. Good management team.
BUY
BUY
December 20, 2004
Likes the company. Even though it hasn't done a whole lot, it's starting to form a pretty good base. Now that the sector is a little bit better than it was, it is pretty ownable now.
Show full opinionHide full opinion
Likes the company. Even though it hasn't done a whole lot, it's starting to form a pretty good base. Now that the sector is a little bit better than it was, it is pretty ownable now.
BUY
BUY
December 2, 2004
Has a few products, but has one primary product in diabetes. If he gets it right, and the animal studies come through in humans, thinks the stock will go from $1 to over $10. The good news is that it has 2/3 other products coming up behind it, so if it drops, will only go down to $0.50.
Show full opinionHide full opinion
Has a few products, but has one primary product in diabetes. If he gets it right, and the animal studies come through in humans, thinks the stock will go from $1 to over $10. The good news is that it has 2/3 other products coming up behind it, so if it drops, will only go down to $0.50.
BUY
BUY
October 4, 2004
Best to own a basket when owing smaller bio techs. Gigh risk/high return. Their diabetes drug, if it flows through, has a huge market potential. News flow has been fairly good. Still early stage. Good management.
Show full opinionHide full opinion
Best to own a basket when owing smaller bio techs. Gigh risk/high return. Their diabetes drug, if it flows through, has a huge market potential. News flow has been fairly good. Still early stage. Good management.
BUY WEAKNESS
BUY WEAKNESS
September 24, 2004
A pretty decent company. Got smeared with the same brush as Conjuchem. Doesn't expect anything this year as it will probably be sold as a tax loss. OK for the long term.
Show full opinionHide full opinion
A pretty decent company. Got smeared with the same brush as Conjuchem. Doesn't expect anything this year as it will probably be sold as a tax loss. OK for the long term.
BUY WEAKNESS
BUY WEAKNESS
August 9, 2004
Very solid management. A phase 2 drug. Overvalued considering the biotech market has dropped so much. Would be more interesting at $.80/$.90.
Show full opinionHide full opinion
Very solid management. A phase 2 drug. Overvalued considering the biotech market has dropped so much. Would be more interesting at $.80/$.90.
TOP PICK
TOP PICK
July 30, 2004
Biotech world has had a tough time in the last month. This company is progressing well. Will take over the clinical development which is very lucrative for the company. Likes management and their pipeline.
Show full opinionHide full opinion
Biotech world has had a tough time in the last month. This company is progressing well. Will take over the clinical development which is very lucrative for the company. Likes management and their pipeline.
TOP PICK
TOP PICK
June 21, 2004
Has an interesting pipeline of products. An early stage product is a diabetes treatment.
Show full opinionHide full opinion
Has an interesting pipeline of products. An early stage product is a diabetes treatment.
BUY
BUY
May 13, 2004
Have the best animal model data that he has ever seen. If they can make the transition to human models, the stock would go to $10. Results could be out by the end of this year or the beginning of next.
Show full opinionHide full opinion
Have the best animal model data that he has ever seen. If they can make the transition to human models, the stock would go to $10. Results could be out by the end of this year or the beginning of next.
Showing 1 to 15 of 17 entries